Tadalafil Safety in Essential Thrombocythemia

Safety Considerations for PDE5 Inhibitors in ET

The American College of Cardiology recommends that phosphodiesterase type 5 (PDE5) inhibitors like tadalafil have shown no specific concerns regarding cardiovascular events in patients with cardiovascular disease, and by extension, in patients with essential thrombocythemia 2, 3
Recent analyses of placebo-controlled and postmarketing surveillance data have demonstrated no new concerns regarding cardiovascular events with PDE5 inhibitors, according to the Mayo Clinic Proceedings 3
The primary contraindication for tadalafil is concomitant use with nitrate medications, which can cause severe hypotension, as stated by the American College of Cardiology 1

Tadalafil has a longer half-life (17.5 hours) compared to other PDE5 inhibitors, as reported by the American College of Cardiology 1
Patients taking tadalafil should avoid nitroglycerine for at least 48 hours due to this extended half-life, according to the American College of Cardiology 1
For patients on long-term nitrate therapy who want to use tadalafil, the decision should be guided by weighing the need for continued nitrate therapy against other available treatment options, as recommended by the American College of Cardiology 1

The Mayo Clinic Proceedings suggests assessing the patient's cardiovascular risk status before prescribing tadalafil 3
For patients with indeterminate cardiovascular risk, consider additional vascular disease assessment, as recommended by the Mayo Clinic Proceedings 3
Ensure the patient is not taking nitrate medications before prescribing tadalafil, according to the American College of Cardiology 1

In patients with both essential thrombocythemia and cardiovascular disease, management of erectile dysfunction should always be considered secondary to maintaining cardiovascular function, as stated by the Mayo Clinic Proceedings 3